Why do drugs that seem promising in Phase 2 trials, go on to fail in Phase 3? A new report from the FDA provides a case study analysis of 22 such medicines, highlighting the importance of large, randomized, controlled trials.

See the source article by following the link below:
Why do drugs that seem promising in Phase 2 trials, go on to fail in Phase 3? A new report from the FDA provides a case study analysis of 22 such medicines, highlighting the importance of large, randomized, controlled trials.